Author of

• 11929

  +

  P2.22 - Poster Session 2 - Epidemiology, Etiology (ID 167)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Prevention & Epidemiology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11932

    +

    P2.22-003 - BIM (BCL2L11) deletion polymorphism is one of major risk factors of Lung cancer in Korean population. (ID 847)

    09:30 - 09:30  |  Author(s): E.N. Cho
    • Abstract

    Background
    BIM (BCL2L11), which encodes a BH3-only protein, is one of major pro-apoptotic factors that facilitate cell death. A 2,903-bp genomic deletion polymorphism in intron 2 of BIM showed 12.3% carrier frequency in East Asian population. This polymorphism results in expression of BIM isoforms lacking the pro-apoptotic BH3. We evaluated whether the presence of the BIM deletion polymorphism is a major risk factors of lung cancer in Korean population.

    Methods
    We designed 1:1 matched case-control study between lung cancer and control subjects. Lung cancer patients and age, gender and smoking status matched control subjects without other types of malignancies were prospectively enrolled from Feb. 2013 to now. Subjects under 18 years old and who denied to present informed consent were excluded. The presence of 2,903-bp genomic DNA deletion polymorphism in intron 2 of BIM were analyzed by PCR and validated by sequencing. BIM deletion polymorphism status and relationship with clinical and pathological parameters were analyzed using chi-square test, t-test, Kaplan-Meyer estimator, and Log-Rank test.

    Results
    There were no statistically significant differences in age, gender and smoking status between lung cancer and control subjects. Twenty-three out of 102 (22.5%) lung cancer patients revealed a BIM deletion polymorphism whereas 9 out of 75 (12%) control subjects showed polymorphism. The odd ratio for the association of BIM deletion polymorphism and lung cancer was 2.139 (p=0.076). Sixty-nine out of 102 (67.6%) lung cancer patients were male and 52 (51%) were smoker. Among them 97 (95%) were non-small cell lung cancer (NSCLC) and 5 (5%) were small cell lung cancer. Adenocarcinoma was the most common histological subtype accounting for 69 out of 97 (71%) in NSCLC. When lung cancer patients were categorized according to the presence of polymorphism status, there was no difference in the age between subjects with and without polymorphism (mean age; 63.3 vs. 63.4 year). Among the lung cancer patients harboring BIM deletion polymorphism, there were more female (9 out of 23, 39%) and non-smokers (15 out of 23, 65%) when compared to those without polymorphism showing 24 out of 79 (30%) female and 35 out of 79 (44%) non-smokers. The histological subtypes between the two groups were not significantly different. A total of 64 out of 102 lung cancer patients had been tested EGFR mutation status. The odd ratio for the association of BIM deletion polymorphism and EGFR activating mutation was 0.87. In lung cancer patients, the BIM deletion polymorphism did not have a statistically significant impact on the clinical outcome of the patients.

    Conclusion
    Our results indicate that BIM deletion polymorphism may be one of major lung cancer risk factors in Korean population. To strengthen our results, we are extending the sample size and are going to perform hierarchical analysis prospectively. To validate our results, we are performing a validation analysis with an external validation dataset from the national cohort.